1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Ventricular Dysfunction, Left in 5 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 5.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| "Treatment with fasudil at a dose of 30 mg/kg/day from days 1 to 28 or from days 29 to 42 decreased the mean pulmonary arterial pressure by 57% and 56%, right ventricular hypertrophy by 31% and 30%, pulmonary arteriolar medial thickness by 50% and 50%, and pulmonary expression of Rho-kinase II by 41% and 28%, respectively, as well as augmented pulmonary expression of eNOS by 16% and 31% and NO by 50% and 76%, respectively, when compared with the vehicle controls." | 1.37 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. ( Chai, CY; Chen, IC; Chen, IJ; Chou, SH; Dai, ZK; Tan, MS; Wu, BN; Wu, JR; Yeh, JL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, R | 1 |
| Su, Y | 1 |
| Yan, J | 1 |
| Sun, H | 1 |
| Wu, J | 1 |
| Liu, W | 1 |
| Xu, Y | 1 |
| Waddingham, MT | 1 |
| Edgley, AJ | 1 |
| Astolfo, A | 1 |
| Inagaki, T | 1 |
| Fujii, Y | 1 |
| Du, CK | 1 |
| Zhan, DY | 1 |
| Tsuchimochi, H | 1 |
| Yagi, N | 1 |
| Kelly, DJ | 1 |
| Shirai, M | 1 |
| Pearson, JT | 1 |
| Mera, C | 1 |
| Godoy, I | 1 |
| RamÃrez, R | 1 |
| Moya, J | 1 |
| Ocaranza, MP | 1 |
| Jalil, JE | 1 |
| Dai, ZK | 1 |
| Wu, BN | 1 |
| Chen, IC | 1 |
| Chai, CY | 1 |
| Wu, JR | 1 |
| Chou, SH | 1 |
| Yeh, JL | 1 |
| Chen, IJ | 1 |
| Tan, MS | 1 |
| Hattori, T | 1 |
| Shimokawa, H | 1 |
| Higashi, M | 1 |
| Hiroki, J | 1 |
| Mukai, Y | 1 |
| Tsutsui, H | 1 |
| Kaibuchi, K | 1 |
| Takeshita, A | 1 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Fasudil improves short-term echocardiographic parameters of diastolic function in patients with type 2 diabetes with preserved left ventricular ejection fraction: a pilot study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus, Type 2; Diastole; Echocardio | 2015 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Diabetes Mellitus, Experimental; Dia | 2015 |
Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Extracellular Signal | 2016 |
Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Cyclic GMP; Endothelin-1; Hypert | 2011 |
Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; DNA-Binding Proteins; Drug Administration Sc | 2004 |